Genetic variation in innate immunity pathways and their potential contribution to the SIRS/CARS debate: Evidence from human studies and animal models

Journal of Innate Immunity

Volumn 2, Issue 5, 2010, Pages 381-394

  Kumpf, Oliver ^a   Schumann, Ralf R ^b  

^a Hanse Klinikum Stralsund   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Animal models; Genomics; Innate immunity; Knockout mice; Pathogen associated molecular patterns; Polymorphism; Sepsis; Toll like receptor

Indexed keywords

CD14 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

COMPENSATORY ANTI INFLAMMATORY RESPONSE SYNDROME; DISEASE COURSE; GENETIC VARIABILITY; HUMAN; INFECTION; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; GENETIC VARIATION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MICE; MICE, KNOCKOUT; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOLL-LIKE RECEPTORS;

EID: 77956064316     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000314269     Document Type: Review

References (107)

1. Adib-Conquy M, Cavaillon JM: Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS Lett 2007; 581: 3723-3733.
2. Bone RC, Grodzin CJ, Balk RA: Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997; 112: 235-243.
3. Beutler B: Innate immunity: an overview. Mol Immunol 2004; 40: 845-859.
4. Medzhitov R: Recognition of microorganisms and activation of the immune response. Nature 2007; 449: 819-826.
5. Volk HD, Reinke P, Docke WD: Clinical aspects: from systemic inflammation to 'immunoparalysis'. Chem Immunol 2000; 74: 162-177.
6. Bone RC: Why sepsis trials fail. JAMA 1996; 276: 565-566.
7. Giannoudis PV, van Griensven M, Tsiridis E, Pape HC: The genetic predisposition to adverse outcome after trauma. J Bone Joint Surg Br 2007; 89: 1273-1279.
8. Kumpf O, Schumann RR: Genetic influence on bloodstream infections and sepsis. Int J Antimicrob Agents 2008; 32(suppl 1):S44-S50.
9. Wunderink RG, Waterer GW: Genetics of sepsis and pneumonia. Curr Opin Crit Care 2003; 9: 384-389.
10. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
11. Barreiro LB, Ben-Ali M, Quach H, Laval G, Patin E, Pickrell JK, Bouchier C, Tichit M, Neyrolles O, Gicquel B, Kidd JR, Kidd KK, Alcais A, Ragimbeau J, Pellegrini S, Abel L, Casanova JL, Quintana-Murci L: Evolutionary dynamics of human toll-like receptors and their different contributions to host defense. PLoS Genet 2009; 5:e1000562.
12. Schroder NW, Schumann RR: Single nucleotide polymorphisms of toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005; 5: 156-164.
13. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-191.
14. Feterowski C, Emmanuilidis K, Miethke T, Gerauer K, Rump M, Ulm K, Holzmann B, Weighardt H: Effects of functional toll-like receptor-4 mutations on the immune response to human and experimental sepsis. Immunology 2003; 109: 426-431.
15. Jessen KM, Lindboe SB, Petersen AL, Eugen-Olsen J, Benfield T: Common TNF-alpha, IL-1 beta, PAI-1, UPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from gram negative sepsis. BMC Infect Dis 2007; 7: 108.
16. Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE, Lowry SF: Human Toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of Gram-negative infections. J Infect Dis 2002; 186: 1522-1525.
17. Lorenz E, Mira JP, Frees KL, Schwartz DA: Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch Intern Med 2002; 162: 1028-1032.
18. von Aulock S, Schroder NW, Gueinzius K, Traub S, Hoffmann S, Graf K, Dimmeler S, Hartung T, Schumann RR, Hermann C: Heterozygous Toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis 2003; 188: 938-943.
19. Ferwerda B, McCall MB, Alonso S, Giamarellos-Bourboulis EJ, Mouktaroudi M, Izagirre N, Syafruddin D, Kibiki G, Cristea T, Hijmans A, Hamann L, Israel S, ElGhazali G, Troye-Blomberg M, Kumpf O, Maiga B, Dolo A, Doumbo O, Hermsen CC, Stalenhoef AF, van Crevel R, Brunner HG, Oh DY, Schumann RR, de la Rua C, Sauerwein R, Kullberg BJ, van der Ven AJ, van der Meer JW, Netea MG: TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci USA 2007; 104: 16645-16650.
20. Van der Graaf CA, Netea MG, Morre SA, Den Heijer M, Verweij PE, Van der Meer JW, Kullberg BJ: Toll-like receptor 4 Asp299Gly/ Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw 2006; 17: 29-34.
21. Hamann L, Kumpf O, Muller M, Visintin A, Eckert J, Schlag PM, Schumann RR: A coding mutation within the first exon of the human MD-2 gene results in decreased lipopolysaccharide-induced signaling. Genes Immun 2004; 5: 283-288.
22. Chien JW, Boeckh MJ, Hansen JA, Clark JG: Lipopolysaccharide binding protein promoter variants influence the risk for gramnegative bacteremia and mortality after allogeneic hematopoietic cell transplantation. Blood 2008; 111: 2462-2469.
23. Fallavena PR, Borges TJ, Paskulin DD, Paludo FJ, Goetze TB, de Oliveira JR, Nobrega OT, Dias FS, Alho CS: The influences of CD14 -260C 1 T polymorphism on survival in ICU critically ill patients. Immunol Invest 2009; 38: 797-811.
24. Sutherland AM, Walley KR, Russell JA: Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit Care Med 2005; 33: 638-644.
25. Gibot S, Cariou A, Drouet L, Rossignol M, Ripoll L: Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002; 30: 969-973.
26. Kabesch M, Hasemann K, Schickinger V, Tzotcheva I, Bohnert A, Carr D, Baldini M, Hackstein H, Leupold W, Weiland SK, Martinez FD, Mutius E, Bein G: A promoter polymorphism in the CD14 gene is associated with elevated levels of soluble CD14 but not with IGE or atopic diseases. Allergy 2004; 59: 520-525.
27. Lamping N, Dettmer R, Schröder NWJ, Pfeil D, Hallatschek W, Burger R, Schumann RR: LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J Clin Invest 1998; 101: 2065-2071.
28. Zweigner J, Gramm HJ, Singer OC, Wegscheider K, Schumann RR: High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 2001; 98: 3800-3808.
29. Kirschning CJ, Schumann RR: Tlr2: cellular sensor for microbial and endogenous molecular patterns. Curr Top Microbiol Immunol 2002; 270: 121-144.
30. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA: A novel polymorphism in the Toll-like receptor 2 gene and its potential association with Staphylococcal infection. Infect Immun 2000; 68: 6398-6401.
31. Schroder NW, Diterich I, Zinke A, Eckert J, Draing C, von Baehr V, Hassler D, Priem S, Hahn K, Michelsen KS, Hartung T, Burmester GR, Gobel UB, Hermann C, Schumann RR: Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J Immunol 2005; 175: 2534-2540.
32. Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, Eckert J, Oh NR, Otchwemah RN, Dietz E, Ehrhardt S, Schroder NW, Bienzle U, Schumann RR: Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci USA 2006; 103: 177-182.
33. Moore CE, Segal S, Berendt AR, Hill AV, Day NP: Lack of association between Toll-like receptor 2 polymorphisms and susceptibility to severe disease caused by Staphylococcus aureus . Clin Diagn Lab Immunol 2004; 11: 1194-1197.
34. Johnson CM, Lyle EA, Omueti KO, Stepensky VA, Yegin O, Alpsoy E, Hamann L, Schumann RR, Tapping RI: Cutting edge: a common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol 2007; 178: 7520-7524.
35. Schuring RP, Hamann L, Faber WR, Pahan D, Richardus JH, Schumann RR, Oskam L: Polymorphism N248S in the human Tolllike receptor 1 gene is related to leprosy and leprosy reactions. J Infect Dis 2009; 199: 1816-1819.
36. Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K, Soudais C, Dupuis S, Feinberg J, Fieschi C, Elbim C, Hitchcock R, Lammas D, Davies G, Al-Ghonaium A, Al-Rayes H, Al-Jumaah S, Al-Hajjar S, Al-Mohsen IZ, Frayha HH, Rucker R, Hawn TR, Aderem A, Tufenkeji H, Haraguchi S, Day NK, Good RA, Gougerot-Pocidalo MA, Ozinsky A, Casanova JL: Pyogenic bacterial infections in humans with Irak-4 deficiency. Science 2003; 299: 2076-2079.
37. von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, Chrabieh M, Mustapha IB, Ghandil P, Camcioglu Y, Vasconcelos J, Sirvent N, Guedes M, Vitor AB, Herrero-Mata MJ, Arostegui JI, Rodrigo C, Alsina L, Ruiz-Ortiz E, Juan M, Fortuny C, Yague J, Anton J, Pascal M, Chang HH, Janniere L, Rose Y, Garty BZ, Chapel H, Issekutz A, Marodi L, Rodriguez-Gallego C, Banchereau J, Abel L, Li X, Chaussabel D, Puel A, Casanova JL: Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008; 321: 691-696.
38. Ku CL, von Bernuth H, Picard C, Zhang SY, Chang HH, Yang K, Chrabieh M, Issekutz AC, Cunningham CK, Gallin J, Holland SM, Roifman C, Ehl S, Smart J, Tang M, Barrat FJ, Levy O, McDonald D, Day-Good NK, Miller R, Takada H, Hara T, Al-Hajjar S, Al-Ghonaium A, Speert D, Sanlaville D, Li X, Geissmann F, Vivier E, Marodi L, Garty BZ, Chapel H, Rodriguez-Gallego C, Bossuyt X, Abel L, Puel A, Casanova JL: Selective predisposition to bacterial infections in Irak-4-deficient children: Irak-4-dependent TLRS are otherwise redundant in protective immunity. J Exp Med 2007; 204: 2407-2422.
39. Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, Ling EY, Frodsham AJ, Walley AJ, Kyrieleis O, Khan A, Aucan C, Segal S, Moore CE, Knox K, Campbell SJ, Lienhardt C, Scott A, Aaby P, Sow OY, Grignani RT, Sillah J, Sirugo G, Peshu N, Williams TN, Maitland K, Davies RJ, Kwiatkowski DP, Day NP, Yala D, Crook DW, Marsh K, Berkley JA, O'Neill L A, Hill AV: A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007; 39: 523-528.
40. Hawn TR, Dunstan SJ, Thwaites GE, Simmons CP, Thuong NT, Lan NT, Quy HT, Chau TT, Hieu NT, Rodrigues S, Janer M, Zhao LP, Hien TT, Farrar JJ, Aderem A: A polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis. J Infect Dis 2006; 194: 1127-1134.
41. Hamann L, Kumpf O, Schuring RP, Alpsoy E, Bedu-Addo G, Bienzle U, Oskam L, Mockenhaupt FP, Schumann RR: Low frequency of the TIRAP S180L polymorphism in Africa, and its potential role in malaria, sepsis, and leprosy. BMC Med Genet 2009; 10: 65.
42. Ferwerda B, Alonso S, Banahan K, McCall MB, Giamarellos-Bourboulis EJ, Ramakers BP, Mouktaroudi M, Fain PR, Izagirre N, Syafruddin D, Cristea T, Mockenhaupt FP, Troye-Blomberg M, Kumpf O, Maiga B, Dolo A, Doumbo O, Sundaresan S, Bedu-Addo G, van Crevel R, Hamann L, Oh DY, Schumann RR, Joosten LA, de la Rua C, Sauerwein R, Drenth JP, Kullberg BJ, van der Ven AJ, Hill AV, Pickkers P, van der Meer JW, O'Neill LA, Netea MG: Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc Natl Acad Sci USA 2009; 106: 10272-10277.
43. Sriskandan S, Altmann DM: The immunology of sepsis. J Pathol 2008; 214: 211-223.
44. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, Cheval C, Monchi M, Teboul JL, Riche F, Leleu G, Arbibe L, Mignon A, Delpech M, Dhainaut JF: Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999; 282: 561-568.
45. Stüber F, Petersen M, Bokelmann F, Schade U: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24: 381-384.
46. Waterer GW, Quasney MW, Cantor RM, Wunderink RG: Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001; 163: 1599-1604.
47. Tang GJ, Huang SL, Yien HW, Chen WS, Chi CW, Wu CW, Lui WY, Chiu JH, Lee TY: Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 2000; 28: 2733-2736.
48. Gordon AC, Lagan AL, Aganna E, Cheung L, Peters CJ, McDermott MF, Millo JL, Welsh KI, Holloway P, Hitman GA, Piper RD, Garrard CS, Hinds CJ: TNF and TNFR polymorphisms in severe sepsis and septic shock: a prospective multicentre study. Genes Immun 2004; 5: 631-640.
49. Teuffel O, Ethier MC, Beyene J, Sung L: Association between tumor necrosis factor-alpha promoter -308A/G polymorphism and susceptibility to sepsis and sepsis mortality: a systematic review and meta-analysis. Crit Care Med 2010; 38: 276-282.
50. Ma P, Chen D, Pan J, Du B: Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 2002; 30: 1046-1050.
51. Read RC, Camp NJ, di Giovine FS, Borrow R, Kaczmarski EB, Chaudhary AG, Fox AJ, Duff GW: An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. J Infect Dis 2000; 182: 1557-1560.
52. Arnalich F, Lopez-Maderuelo D, Codoceo R, Lopez J, Solis-Garrido LM, Capiscol C, Fernandez-Capitan C, Madero R, Montiel C: Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin Exp Immunol 2002; 127: 331-336.
53. Santtila S, Savinainen K, Hurme M: Presence of the IL-1RA allele 2 (IL1RN * 2) is associated with enhanced il-1beta production in vitro. Scand J Immunol 1998; 47: 195-198.
54. Saleh M, Vaillancourt JP, Graham RK, Huyck M, Srinivasula SM, Alnemri ES, Steinberg MH, Nolan V, Baldwin CT, Hotchkiss RS, Buchman TG, Zehnbauer BA, Hayden MR, Farrer LA, Roy S, Nicholson DW: Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 2004; 429: 75-79.
55. Sutherland AM, Walley KR, Manocha S, Russell JA: The association of interleukin 6 haplotype clades with mortality in critically ill adults. Arch Intern Med 2005; 165: 75-82.
56. Schluter B, Raufhake C, Erren M, Schotte H, Kipp F, Rust S, Van Aken H, Assmann G, Berendes E: Effect of the interleukin-6 promoter polymorphism (-174G/C) on the incidence and outcome of sepsis. Crit Care Med 2002; 30: 32-37.
57. Tischendorf JJ, Yagmur E, Scholten D, Vidacek D, Koch A, Winograd R, Gressner AM, Trautwein C, Wasmuth HE, Lammert F: The interleukin-6 (IL6) -174G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL6. Int J Immunogenet 2007; 34: 413-418.
58. Taudorf S, Krabbe KS, Berg RM, Moller K, Pedersen BK, Bruunsgaard H: Common studied polymorphisms do not affect plasma cytokine levels upon endotoxin exposure in humans. Clin Exp Immunol 2008; 152: 147-152.
59. Jones KG, Brull DJ, Brown LC, Sian M, Greenhalgh RM, Humphries SE, Powell JT: Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001; 103: 2260-2265.
60. Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, Lowe GD, Humphries SE: Interleukin-6 gene -174G 1 C and -572G 1 C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001; 21: 1458-1463.
61. Opal SM, DePalo VA: Anti-inflammatory cytokines. Chest 2000; 117: 1162-1172.
62. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW: Interleukin-10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95: 9465-9470.
63. Shu Q, Fang X, Chen Q, Stuber F: IL-10 polymorphism is associated with increased incidence of severe sepsis. Chin Med J (Engl) 2003; 116: 1756-1759.
64. Gallagher PM, Lowe G, Fitzgerald T, Bella A, Greene CM, McElvaney NG, O'Neill SJ: Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 2003; 58: 154-156.
65. Shu Q, Shi CC, Zhang XH, Shi Z, Shi SS, Fang XM, Chen QX, Stuber F: Interleukin 10.G microsatellite in the promoter region of the interleukin-10 gene in severe sepsis. Chin Med J (Engl) 2006; 119: 197-201.
66. Choi EH, Foster CB, Taylor JG, Erichsen HC, Chen RA, Walsh TJ, Anttila VJ, Ruutu T, Palotie A, Chanock SJ: Association between chronic disseminated candidiasis in adult acute leukemia and common IL4 promoter haplotypes. J Infect Dis 2003; 187: 1153-1156.
67. Bozzi A, Reis BS, Pereira PP, Pedroso EP, Goes AM: Interferon-gamma and interleukin-4 single nucleotide gene polymorphisms in paracoccidioidomycosis. Cytokine 2009; 48: 212-217.
68. Adewoye AH, Nolan VG, Ma Q, Baldwin C, Wyszynski DF, Farrell JJ, Farrer LA, Steinberg MH: Association of polymorphisms of igf1r and genes in the transforming growth factor-beta/bone morphogenetic protein pathway with bacteremia in sickle cell anemia. Clin Infect Dis 2006; 43: 593-598.
69. Saltzman BS, Yamamoto JF, Decker R, Yokochi L, Theriault AG, Vogt TM, Le Marchand L: Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia. Cancer Res 2008; 68: 1236-1244.
70. Leon LR: Invited review: Cytokine regulation of fever: studies using gene knockout mice. J Appl Physiol 2002; 92: 2648-2655.
71. Miyake K: Innate immune sensing of pathogens and danger signals by cell surface Tolllike receptors. Semin Immunol 2007; 19: 3-10.
72. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S: Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the LPS gene product. J Immunol 1999; 162: 3749-3752.
73. O'Brien AD, Rosenstreich DL, Scher I, Campbell GH, MacDermott RP, Formal SB: Genetic control of susceptibility to salmonella typhimurium in mice: role of the LPS gene. J Immunol 1980; 124: 20-24.
74. Netea MG, Van Der Graaf CA, Vonk AG, Verschueren I, Van Der Meer JW, Kullberg BJ: The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 2002; 185: 1483-1489.
75. Wurfel MM, Monks BG, Ingalls RR, Dedrick RL, Delude R, Zhou D, Lamping N, Schumann RR, Thieringer R, Fenton MJ, Wright SD, Golenbock D: Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med 1997; 186: 2051-2056.
76. Jack RS, Fan X, Bernheiden M, Rune G, Ehlers M, Weber A, Kirsch G, Mentel R, Furll B, Freudenberg M, Schmitz G, Stelter F, Schutt C: Lipopolysaccharide- binding protein is required to combat a murine Gramnegative bacterial infection. Nature 1997; 389: 742-745.
77. Haziot A, Ferrero E, Kontgen F, Hijiya N, Yamamoto S, Silver J, Stewart CL, Goyert SM: Resistance to endotoxin shock and reduced dissemination of Gram-negative bacteria in CD14-deficient mice. Immunity 1996; 4: 407-414.
78. Takeuchi O, Hoshino K, Akira S: Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to staphylococcus aureus infection. J Immunol 2000; 165: 5392-5396.
79. Mancuso G, Midiri A, Beninati C, Biondo C, Galbo R, Akira S, Henneke P, Golenbock D, Teti G: Dual role of TLR2 and myeloid differentiation factor 88 in a mouse model of invasive group B Streptococcal disease. J Immunol 2004; 172: 6324-6329.
80. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S: Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999; 11: 115-122.
81. Weighardt H, Kaiser-Moore S, Vabulas RM, Kirschning CJ, Wagner H, Holzmann B: Cutting edge: Myeloid differentiation factor deficiency improves resistance against sepsis caused by polymicrobial infection. J Immunol 2002; 169: 2823-2827.
82. Peck-Palmer OM, Unsinger J, Chang KC, Davis CG, McDunn JE, Hotchkiss RS: Deletion of MyD88 markedly attenuates sepsisinduced T and B lymphocyte apoptosis but worsens survival. J Leukoc Biol 2008; 83: 1009-1018.
83. Horng T, Barton GM, Flavell RA, Medzhitov R: The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002; 420: 329-333.
84. Togbe D, Aurore G, Noulin N, Quesniaux VF, Schnyder-Candrian S, Schnyder B, Vasseur V, Akira S, Hoebe K, Beutler B, Ryffel B, Couillin I: Nonredundant roles of TIRAP and MyD88 in airway response to endotoxin, independent of Trif, IL-1 and IL-18 pathways. Lab Invest 2006; 86: 1126-1135.
85. Jeyaseelan S, Manzer R, Young SK, Yamamoto M, Akira S, Mason RJ, Worthen GS: Toll-IL-1 receptor domain-containing adaptor protein is critical for early lung immune responses against Escherichia coli lipopolysaccharide and viable Escherichia coli . J Immunol 2005; 175: 7484-7495.
86. Jeyaseelan S, Young SK, Yamamoto M, Arndt PG, Akira S, Kolls JK, Worthen GS: Toll/IL-1R domain-containing adaptor protein (TIRAP) is a critical mediator of antibacterial defense in the lung against Klebsiella pneumoniae but not Pseudomonas aeruginosa . J Immunol 2006; 177: 538-547.
87. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G: Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996; 184: 1397-1411.
88. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Kronke M, Mak TW: Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993; 73: 457-467.
89. Dinarello CA: Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-550.
90. Zheng H, Fletcher D, Kozak W, Jiang M, Hofmann KJ, Conn CA, Soszynski D, Grabiec C, Trumbauer ME, Shaw A, et al: Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. Immunity 1995; 3: 9-19.
91. Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, McDowell J, Paskind M, Rodman L, Salfeld J, et al: Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 1995; 80: 401-411.
92. Labow M, Shuster D, Zetterstrom M, Nunes P, Terry R, Cullinan EB, Bartfai T, Solorzano C, Moldawer LL, Chizzonite R, McIntyre KW: Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J Immunol 1997; 159: 2452-2461.
93. Hultgren OH, Svensson L, Tarkowski A: Critical role of signaling through IL-1 receptor for development of arthritis and sepsis during Staphylococcus aureus infection. J Immunol 2002; 168: 5207-5212.
94. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368: 339-342.
95. van der Poll T, Keogh CV, Guirao X, Buurman WA, Kopf M, Lowry SF: Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 1997; 176: 439-444.
96. Sewnath ME, Olszyna DP, Birjmohun R, ten Kate FJ, Gouma DJ, van Der Poll T: IL-10-deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J Immunol 2001; 166: 6323-6331.
97. Latifi SQ, O'Riordan MA, Levine AD: Interleukin-10 controls the onset of irreversible septic shock. Infect Immun 2002; 70: 4441-4446.
98. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S: Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993; 90: 770-774.
99. McCartney-Francis N, Jin W, Wahl SM: Aberrant toll receptor expression and endotoxin hypersensitivity in mice lacking a functional TGF-beta 1 signaling pathway. J Immunol 2004; 172: 3814-3821.
100. Osuchowski MF, Welch K, Yang H, Siddiqui J, Remick DG: Chronic sepsis mortality characterized by an individualized inflammatory response. J Immunol 2007; 179: 623-630.
101. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC: Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the genetic and inflammatory markers of sepsis (genims) study. Arch Intern Med 2007; 167: 1655-1663.
102. Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz Y, Danner RL, Natanson C: Risk and the efficacy of anti-inflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166: 1197-1205.
103. Pompanon F, Bonin A, Bellemain E, Taberlet P: Genotyping errors: causes, consequences and solutions. Nat Rev Genet 2005; 6: 847-859.
104. Buras JA, Holzmann B, Sitkovsky M: Animal models of sepsis: setting the stage. Nat Rev Drug Discov 2005; 4: 854-865.
105. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF: A network-based analysis of systemic inflammation in humans. Nature 2005; 437: 1032-1037.
106. Beutler B, Poltorak A: Sepsis and evolution of the innate immune response. Crit Care Med 2001; 29:S2-S6; discussion S6-S7.
107. Nagpal K, Plantinga TS, Wong J, Monks BG, Gay NJ, Netea MG, Fitzgerald KA, Golenbock DT: A TIR domain variant of MyD88 adapter-like (Mal)/TIRAP results in loss of MyD88 binding and reduced TLR2/TLR4 signaling. J Biol Chem 2009; 284: 25742-25748.